이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Aditxt 관리

관리 기준 확인 3/4

Aditxt's CEO는 Amro Albanna, Jan2017 에 임명되었습니다 의 임기는 7.42 년입니다. 총 연간 보상은 $ 519.23K, 83.2% 로 구성됩니다. 83.2% 급여 및 16.8% 보너스(회사 주식 및 옵션 포함). 는 $ 545.74 가치에 해당하는 회사 주식의 0.019% 직접 소유합니다. 545.74. 경영진과 이사회의 평균 재임 기간은 각각 3.4 년과 5.5 년입니다.

주요 정보

Amro Albanna

최고 경영자

US$519.2k

총 보상

CEO 급여 비율	83.2%
CEO 임기	7.5yrs
CEO 소유권	0.02%
경영진 평균 재임 기간	3.5yrs
이사회 평균 재임 기간	5.6yrs

최근 관리 업데이트

Recent updates

Aditxt gains on regaining compliance with Nasdaq listing requirements

Sep 29

Aditxt climbs 32% postmarket after completing 1-for-50 reverse stock split

Sep 13

Aditxt stock surges 61% on positive preclinical toxicity study of its psoriasis drug candidate

Jul 08

CEO 보상 분석

Amro Albanna 의 보수는 Aditxt 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$41m
Dec 31 2023	US$519k	US$432k	-US$33m
Sep 30 2023	n/a	n/a	-US$30m
Jun 30 2023	n/a	n/a	-US$27m
Mar 31 2023	n/a	n/a	-US$28m
Dec 31 2022	US$500k	US$500k	-US$28m
Sep 30 2022	n/a	n/a	-US$43m
Jun 30 2022	n/a	n/a	-US$46m
Mar 31 2022	n/a	n/a	-US$46m
Dec 31 2021	US$2m	US$280k	-US$46m
Sep 30 2021	n/a	n/a	-US$27m
Jun 30 2021	n/a	n/a	-US$20m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	US$252k	US$252k	-US$9m
Sep 30 2020	n/a	n/a	-US$5m
Jun 30 2020	n/a	n/a	-US$4m
Mar 31 2020	n/a	n/a	-US$6m
Dec 31 2019	US$2m	US$252k	-US$6m
Sep 30 2019	n/a	n/a	-US$5m
Jun 30 2019	n/a	n/a	-US$6m
Mar 31 2019	n/a	n/a	-US$5m
Dec 31 2018	US$180k	US$180k	-US$6m
Dec 31 2017	US$198k	US$51k	-US$852k

보상 대 시장: Amro 의 총 보상 ($USD 519.23K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 683.56K ).

보상과 수익: 회사가 수익성이 없는 동안 Amro 의 보상이 증가했습니다.

CEO

Amro Albanna (54 yo)

7.5yrs

테뉴어

US$519,233

보상

Mr. Amro A. Albanna has been Chief Executive Officer and a Director of Aditxt, Inc. (formerly known as ADiTx Therapeutics, Inc.) since 2017 and serves as its Chairman of the Board and served as its Preside...

리더십 팀

이름	위치	테뉴어	보상	소유권
Amro Albanna	Co-Founder	7.5yrs	US$519.23k	0.019% $ 519.2
Shahrokh Shabahang	Co-Founder	7.5yrs	US$358.84k	0.38% $ 10.5k
Thomas Farley	Chief Financial Officer	2.8yrs	US$381.45k	0.0040% $ 109.5
Corinne Pankovcin	Chief Commercialization Officer	2.3yrs	US$390.33k	0.0043% $ 117.7
Rowena Albanna	Chief Operating Officer	4yrs	데이터 없음	0.0043% $ 117.7
Jennifer Lee	Director of Human Resources	3.5yrs	데이터 없음	데이터 없음
Dolly Tyan	Senior Vice President of Clinical Development – Transplantation	3.5yrs	데이터 없음	데이터 없음
Ge Chen	Senior Vice President of Preclinical Research & Discovery	2.5yrs	데이터 없음	데이터 없음

3.5yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: ADTX 의 관리팀은 경험 ( 3.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Amro Albanna	Co-Founder	7.5yrs	US$519.23k	0.019% $ 519.2
Shahrokh Shabahang	Co-Founder	7.5yrs	US$358.84k	0.38% $ 10.5k
Jeffrey Runge	Independent Director	4yrs	US$15.00k	0.00030% $ 8.2
Charles Athle Nelson	Independent Director	less than a year	데이터 없음	0.013% $ 357.5
Brian Brady	Independent Director	5.6yrs	US$15.00k	0.00065% $ 17.8

5.6yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: ADTX 의 이사회는 경험(평균 재직 기간 5.5 년)으로 간주됩니다.

Aditxt 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Aditxt, Inc. Announces Board Changes

Insufficient new directors

Aditxt, Inc. Announces Resignation of Matthew Shatzkes as Chief Legal Officer, General Counsel and Corporate Secretary

Aditxt, Inc., Annual General Meeting, Aug 16, 2023

Aditxt, Inc., Annual General Meeting, Jun 24, 2022

High number of new directors

Recent updates

Aditxt, Inc. announced delayed 10-Q filing

Aditxt, Inc. announced that it expects to receive $4.2 million in funding

Aditxt, Inc. announced delayed annual 10-K filing

Aditxt, Inc. announced that it has received $6.000003 million in funding

Aditxt Regains Compliance with Nasdaq Stockholders' Equity Requirement

Aditxt, Inc. (NasdaqCM:ADTX) entered into an agreement and plan of merger to acquire Evofem Biosciences, Inc. (OTCPK:EVFM) from shareholders.

Third quarter 2023 earnings released: US$47.13 loss per share (vs US$211 loss in 3Q 2022)

Aditxt, Inc. Announces Board Changes

Nasdaq Hearings Panel Grants Aditxt an Exception through December 26, 2023 to Allow Aditxt to Complete its Plan to Demonstrate Compliance with the Equity Rule

Aditxt Receives Written Notice from Nasdaq

Aditxt, Inc. announced that it has received $10 million in funding

Aditxt, Inc. announced that it expects to receive $10 million in funding

New major risk - Negative shareholders equity

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$6.42 loss in 2Q 2022)

Insufficient new directors

Aditxt, Inc. Announces Resignation of Matthew Shatzkes as Chief Legal Officer, General Counsel and Corporate Secretary

Aditxt, Inc., Annual General Meeting, Aug 16, 2023

Aditxt Receives Notice from Nasdaq Due to Non-Compliance with Minimum Stockholders Equity Requirement

Aditxt, Inc. Announces Development and Publication of Mathematical Model for Predicting Longevity and Variations of Immune Response to Immunization to SARS-CoV-2 Infection

Aditxt Regains Compliance with Nasdaq Listing Requirements

Aditxt gains on regaining compliance with Nasdaq listing requirements

Aditxt, Inc. has completed a Follow-on Equity Offering.

Aditxt climbs 32% postmarket after completing 1-for-50 reverse stock split

Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI™-100 Advancing it Closer to First-in-Human Trials

Aditxt stock surges 61% on positive preclinical toxicity study of its psoriasis drug candidate

Aditxt, Inc., Annual General Meeting, Jun 24, 2022

Aditxt Submits Two Requests for Emergency Use Authorization to FDA for AditxtScore™ for COVID-19 Tests Which Measure the Quantity and Quality of Antibodies Against COVID-19 and its Variants Including Omicron

Aditxt Provides Update on AditxtReprogramming’s Apoptotic DNA Immunotherapy Therapeutic Platform

High number of new directors

Aditx Therapeutics, Inc. Announces Enhancements to Its Aditxtscore for COVID-19

Aditxt adds Lauren Chung to board of directors

Co-Founder exercised options to buy US$60k worth of stock.

Eazy Testing Inc. Becomes AditxtScore™ Channel Partner, to Offer AditxtScore™ for COVID-19 Immunity Status Monitoring with its Walk-In, Concierge, and Pre-Flight Services

New 90-day high: US$4.10

ADiTx Therapeutics, Inc. Appoints Dolly B. Tyan as Senior Vice President of Clinical Development - Transplantation

Aditx Therapeutics, Inc. Announces the Operational Launch of the AditxtScore™ Immune Monitoring Platform

New 90-day high: US$2.61

Aditxt Signs Distribution Agreement with Todos Medical Ltd. for Aditxtscore™ for Covid-19 Immune Monitoring Service

Aditxt, Todos Medical in distribution pact for for COVID-19 immune monitoring

New 90-day high: US$2.39

We Think ADiTx Therapeutics (NASDAQ:ADTX) Can Afford To Drive Business Growth

Aditx Therapeutics, Inc. Appoints Anthony Voorhies as Head of Business Development for AditxtScore

Aditx Therapeutics, Inc. Secures CLIA Certification for AditxtScore™ Laboratory Operations in Richmond, VA, and Plans to Launch AditxtScore™ for COVID-19 as a Lab Developed Test

ADiTx Therapeutics, Inc. has completed a Composite Units Offering in the amount of $9.6 million.

ADiTx Therapeutics, Inc. has completed an IPO in the amount of $11.040012 million.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령